ArticleDrug safety2018
Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors.
Article in Drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis.CNS drugs · 2021Pooled it
- Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies.Journal of personalized medicine · 2026Review
- The Impact of Sex and Age on Antipsychotic Serum Concentrations.Schizophrenia bulletin · 2026Article
- Serotonin syndrome risk with concomitant opioid and serotonergic antidepressant use: a multinational pharmacovigilance study.Frontiers in pharmacology · 2026Article
- Barriers and solutions in women's health research and clinical care: a call to action.Lancet regional health. Americas · 2025Review
- Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system.Scientific reports · 2024Article
- The Influence of the Estrous Cycle on Neuropeptide S Receptor-Mediated Behaviors.The Journal of pharmacology and experimental therapeutics · 2024Article
- Potential Differences in Psychedelic Actions Based on Biological Sex.Endocrinology · 2024Review
- Impact of sex on antidepressant discontinuation in groups of similar cytochrome P450 phenotypes.The mental health clinician · 2023Article
- Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database.Drug safety · 2023Article
- Sex, Gender, and the Regulation of Prescription Drugs: Omissions and Opportunities.International journal of environmental research and public health · 2023Review
- Intersection of Sex and Depression: Pathogenesis, Presentation, and Treatments.Handbook of experimental pharmacology · 2023Article
- A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021Review
- Improving clinical outcomes through attention to sex and hormones in research.Nature reviews. Endocrinology · 2021Review
- A Drug Safety Surveillance Study of a Ciprofloxacin/Dexamethasone Ophthalmic Fixed Combination in Peruvian Population.Pharmacy (Basel, Switzerland) · 2021Article
- Effect of Estrous Cycle on Behavior of Females in Rodent Tests of Anxiety.Frontiers in psychiatry · 2021Review
- Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization.Pharmaceutics · 2020Review
- Individualized medicine: Sex, hormones, genetics, and adverse drug reactions.Pharmacology research & perspectives · 2019Review
- Comparison of the extent and prevalence of prescription of potentially inappropriate medications prescribed to geriatric age group residing in old-age homes versus those receiving care from tertiary care hospital using Beers criteria.Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral studies have investigated sex as a risk factor for the occurrence of adverse drug reactions (ADRs) and found that women are more likely to experience ADRs than men.
objectiveThe aim of this explorative study was to investigate whether differences exist in reported ADRs of selective serotonin reuptake inhibitors (SSRIs) for men and women in the database of the Netherlands Pharmacovigilance Centre Lareb.
methodsA ratio of reports concerning women and men, corrected for the number of users, was calculated for all the ADRs reported on SSRIs.
resultsWe found that 16 ADRs were statistically significantly more reported in women than men, and four ADRS were reported more in men than women.
conclusionADRs more reported in women than men when using SSRIs were usually dose-related ADRs or commonly occurring ADRs. Differences in the pharmacokinetics of SSRIs between men and women may explain why these reports of dose-related ADRs when using SSRIs concern women more than men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.